3-(N-Cbz-4-哌啶基)-3-氧代丙酸乙酯 | 167414-75-7

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(N-Cbz-4-哌啶基)-3-氧代丙酸乙酯
• 中文别名: 3-(N-CBZ-哌啶-4-基)-3-氧代丙酸乙酯；3-(1-苄氧羰基哌啶-4-基)-3-氧代丙酸乙酯
• 英文名称: benzyl 4-(3-ethoxy-3-oxopropanoyl)piperidine-1-carboxylate
• CAS: 167414-75-7
• 化学式: C₁₈H₂₃NO₅
• 分子量: 333.384
• InChiKey: HSYRPXCJJXOCKE-UHFFFAOYSA-N

物化性质

• 沸点：
  461.8±45.0 °C(Predicted)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(2-Ethoxycarbonyl-acetyl)-piperidine-1-carboxylic acid benzyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(2-Ethoxycarbonyl-acetyl)-piperidine-1-carboxylic acid benzyl ester
CAS number: 167414-75-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C18H23NO5
Molecular weight: 333.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-(N-CBZ-哌啶-4-基)-3-氧代丙酸乙酯是一种医药中间体，可通过三步合成过程从4-哌啶甲酸制备得到。

反应信息

• 作为反应物：
  描述：

  3-(N-Cbz-4-哌啶基)-3-氧代丙酸乙酯 在 盐酸 、 sodium hydroxide 、 盐酸羟胺 、 氢溴酸 作用下， 以 丙酮 为溶剂， 反应 20.55h， 生成 3-(4-piperidyl)isoxazol-5-ol hydrobromide
  参考文献：
  名称：

  部分GABAA受体激动剂。一系列4,5,6,7-四氢异恶唑并[5,4-c]吡啶-3-醇的非环状类似物的合成及体外药理作用。

  摘要：

  5-（4-哌啶基）异恶唑-3-醇（4-PIOL，10），4-氨基丁酸（GABA，1）和GABAA激动剂4,5,6,7-四氢异恶唑的结构类似物[5,4 -c] pyridin-3-ol（THIP，5）是低效的部分GABAA激动剂。从10种生物立体异构体衍生的许多化合物，包括5-（4-哌啶基）异噻唑-3-醇（11），3-（4-哌啶基）异噻唑-5-醇（12），5-（1,2,3合成了1,6-四氢吡啶-4-基）异噻唑-3-醇（13）和5-（1,2,3,6-四氢吡啶-4-基）异噻唑-3-醇（14） GABAA受体配体。尽管这些化合物均未显着影响GABAB受体的结合或GABA的吸收，但它们在低微摩尔范围内显示出对GABAA受体位点的亲和力。使用培养的大脑皮层神经元和全细胞膜片钳技术，这些化合物相对于完整GABAA激动剂的功效，测定了异胍卡因（8）（20 microM）。11的相对功效比10（IC50 =

  DOI：

  10.1021/jm00017a014
• 作为产物：
  描述：

  4-哌啶甲酸 在 4-二甲氨基吡啶 、 sodium hydroxide 、 magnesium chloride 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 14.0h， 生成 3-(N-Cbz-4-哌啶基)-3-氧代丙酸乙酯
  参考文献：
  名称：

  吡唑并嘧啶类化合物及其药物组合物和其在制 药中的应用

  摘要：

  提供结构式（I）所示的吡唑并嘧啶类化合物，其为活性成分的药物组合物，它们的制备方法，以及在制备TRPC6调节剂探针药物及在制备防治肾小球疾病及心肌肥大症相关药物中的应用。本发明中的吡唑并嘧啶及其衍生物可制备成各种形式的药物制剂，包括口服、注射、肺吸入制剂、透皮制剂，具体包括注射剂、口服液、片剂、胶囊剂、颗粒剂、气雾剂、粉雾剂、喷雾剂、贴剂等。

  公开号：

  CN103694242B

文献信息

• [EN] AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF<br/>[FR] AZAINDAZOLES COMME MODULATEURS DE LA KINASE BTK ET LEUR UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011019780A1

  公开（公告）日：2011-02-17

  Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, (I) are useful as kinase modulators, including Btk modulation, wherein A1, A2, A3, R4, are as defined herein.

  具有化学式(I)的化合物，以及其对映体、非对映异构体、药用可接受的盐，(I)可用作激酶调节剂，包括Btk调节，在此处定义了A1、A2、A3、R4。
• [EN] PIPERIDIN-PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H4 RECEPTOR<br/>[FR] DÉRIVÉS DE PIPÉRIDINE-PYRIMIDINE COMME ANTAGONISTES DES RÉCEPTEURS HISTAMINIQUES H4
  申请人：PALAU PHARMA SA

  公开号：WO2010094721A1

  公开（公告）日：2010-08-26

  Piperidin-pyrimidine derivatives of formula (I), wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine H4 receptor antagonists.

  Piperidin-pyrimidine衍生物的化学式（I），其中不同取代基的含义如描述中所示。这些化合物可用作组胺H4受体拮抗剂。
• Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
  申请人：Berlex Laboratories, Inc.

  公开号：US06372751B1

  公开（公告）日：2002-04-16

  This invention is directed to aryl and heterocyclyl substituted pyrimidine derivatives selected from the following formulae: wherein Z1, Z2, R1, R2, R3, R4, R5 and R6 are defined herein. These compounds are useful as anti-coagulants.

  这项发明涉及从以下公式中选择的芳基和杂环基取代的嘧啶衍生物： 其中Z1、Z2、R1、R2、R3、R4、R5和R6在此处定义。这些化合物可用作抗凝剂。
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2012158810A1

  公开（公告）日：2012-11-22

  The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.

  本公开提供了一些化合物和药用盐，它们是酪氨酸激酶抑制剂，特别是BLK、BMX、EGFR、HER2、HER4、ITK、JAK3、TEC、BTK和TXK，因此适用于治疗通过抑制酪氨酸激酶可治疗的疾病，如癌症和炎症性疾病，如关节炎等。还提供了含有这些化合物和药用盐的药物组合物，以及制备这些化合物和药用盐的方法。
• [EN] THERAPEUTIC METHODS AND COMPOUNDS<br/>[FR] PROCÉDÉS ET COMPOSÉS THÉRAPEUTIQUES
  申请人：UNIV RUTGERS

  公开号：WO2020219591A1

  公开（公告）日：2020-10-29

  The invention provides a compound of formula I: (I) or a pharmaceutically acceptable salt thereof, wherein R1-R5 Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful to treat malaria.

  该发明提供了一种化合物的公式I：(I)或其药用可接受的盐，其中R1-R5 Y具有规范中描述的任何值，以及包含公式I化合物的组合物。这些化合物可用于治疗疟疾。